Key Morningstar Metrics for Eli Lilly

• : $900.00
• : ★★★

• Morningstar Economic Moat Rating

  : Wide

• Morningstar Uncertainty Rating

  : High

What We Thought of Eli Lilly’s Earnings

Eli Lilly LLY reported 56% revenue growth and 156% non-GAAP EPS growth in the first quarter, and management raised full-year revenue guidance by $2 billion to a range of $82 billion-$85 billion, implying 28% growth at the midpoint. Shares rose 10% intraday on April 30.

Why it matters: Given the significant price drop in cash-pay markets for obesity drug Zepbound in the United States starting in late 2025 and diabetes drug Mounjaro’s China launch, there was some uncertainty about how well market volume growth and share gains would…